Patient-reported outcomes evaluating palliative radiotherapy and chemotherapy in patients with oesophageal cancer: A systematic review

Acta Oncologica

Volumn 52, Issue 4, 2013, Pages 679-690

  Amdal, Cecilie Delphin ^a   Jacobsen, Anne Birgitte ^a   Guren, Marianne Gronlie ^a   Bjordal, Kristin ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLIC ACID; IRINOTECAN; METHOTREXATE; MITOMYCIN; OXALIPLATIN;

ADD ON THERAPY; ADVANCED CANCER; ALOPECIA; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ASSESSMENT; COMBINATION CHEMOTHERAPY; DYSPHAGIA; ERYTHEMA; ESOPHAGUS CANCER; EXTERNAL BEAM RADIOTHERAPY; HAND FOOT SYNDROME; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFERENCE DATABASE; REVIEW; SIDE EFFECT; SYMPTOM; SYSTEMATIC REVIEW; WEIGHT REDUCTION; CANCER PATIENT; CHEMORADIOTHERAPY; NAUSEA; PHASE 3 CLINICAL TRIAL (TOPIC); TREATMENT OUTCOME; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRACHYTHERAPY; CARCINOMA; ESOPHAGEAL NEOPLASMS; HUMANS; PALLIATIVE CARE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SELF REPORT; TREATMENT OUTCOME;

EID: 84875914987     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2012.731521     Document Type: Review

References (52)

1. Berger B, B elka C. E vidence-based radiation oncology: Ooesophagus. Radiother Oncol 2009; 92: 276-90.
2. Homs M Y, G aast A, S iersema P D, S teyerberg E W, K uipers E J. Chemotherapy for metastatic carcinoma of the esophaguSand gastro-esophageal junction. Cochrane Database Syst Rev 2006; 4: CD004063.
3. Blazeby J M. M easurement of outcome. S urg Oncol 2001; 10: 127-33.
4. Efficace F, B ottomley A, O soba D, G otay C, Flechtner H, D'haese S, et al. Beyond the development of health-related quality-of-life (HRQOL) measures: A checklist foRevaluating HRQOL outcomes in cancer clinical trials-does HRQOL evaluation in prostate cancer research inform clinical decision making? J Clin Oncol 2003; 21: 3502-11.
5. Higgins JPT, Green S. C ochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Cochrane collaboration 2009 Sep.
6. Bottomley A, J ones D, C laassens L. Patient-reported outcomes: Assessment and current perspectives of the guidelines of the Food and Drug Administration and the refl ection paper of the European MedicineSagency. Eur J Cancer 2009; 45: 347-53.
7. Trotti A, ColevaSa D, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13: 176-81.
8. Blazeby J M, A lderson D, W instone K, S teyn R, H ammerliDe, Arraras J, et al. Development of an EORTC questionnaire module to be used in quality of life assessment for patients with oesophageal cancer. The EORTC Quality of life Study Group. Eur J Cancer 1996; 32A: 1912-7.
9. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviewSand meta-analyses: The PRISMA statement. J Clin Epidemiol 2009; 62: 1006-12.
10. Higgins J P, A ltman D G, G otzsche P C, J uni P, M oher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
11. Ajani JA, B aker J, P isters PW, H o L, M ansfi eld PF, F eig BW, et al. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: Results of a phase II study. Cancer 2002; 94: 641-6.
12. Ajani JA, M oiseyenko VM, T julandin S, M ajliSa, C onstenla M, Boni C, et al. Quality of life with docetaxel plus cisplatin and fl uorouracil compared with cisplatin and fl uorouracil from a phase III trial for advanced gastric or gastroesophageaLadenocarcinoma: The V-325 Study Group. J Clin Oncol 2007; 25: 3210-6.
13. Bamias A, Hill M E, Cunningham D, Norman AR, Ahmed F Y, Webb A, et al. Epirubicin, cisplatin, and protracted venous infusion of 5-fl uorouracil foResophagogastriCadenocarcinoma: Response, toxicity, quality of life, and survival. Cancer 1996; 77: 1978-85.
14. Bergquist H, Wenger U, Johnsson E, Nyman J, Ejnell H, HammerliDe, et al. Stent insertion oRendoluminal brachytherapy as palliation of patients with advanced cancer of the esophaguSand gastroesophageal junction. Results of a randomized, controlled clinical trial. Dis Esophagus 2005; 18: 131-9.
15. Burmeister B H, W alpole E T, B urmeisteRe A, T homas J, Thomson DB, Harvey JA, et al. Feasibility of chemoradiation therapy with protracted infusion of 5-fl uorouracil foResophageal cancer patients noTsuitable for cisplatin. Int J Clin Oncol 2005; 10: 256-61.
16. Cho SH, Chung IJ, S ong SY, Yang DH, B yun JR, K im YK, et al. Bi-weekly chemotherapy of paclitaxeLand cisplatin in patients with metastatic or recurrent esophageal cancer. J Korean Med Sci 2005; 20: 618-23.
17. Conroy T, E tienne PL, A deniSa, D ucreux M, Paillot B, Oliveira J, et al. Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: Response, toxicity, quality of life and survival. Ann Oncol 2002; 13: 721-9.
18. Cunningham D, S tarling N, R ao S, I veson T, N icolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanceDesophagogastric cancer. N Engl J Med 2008; 358: 36-46.
19. Curran D, Pozzo C, Zaluski J, Dank M, Barone C, Valvere V, et al. Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach oResophagogastric junction treated with irinotecan combined with 5-fl uorouraciLand foliniCacid: Results of a randomised phase III trial. Qual Life Res 2009; 18: 853-61.
20. Dank M, Z aluski J, B arone C, V alvere V, Y alcin S, P eschel C, et al. Randomized phase III study comparing irinotecan combined with 5-fl uorouraciLand foliniCacid to cisplatin combined with 5-fl uorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach oResophagogastric junction. Ann Oncol 2008; 19: 1450-7.
21. Findlay M, C unningham D, N orman A, M ansi J, N icolson M, Hickish T, et al. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fl uorouracil (ECF). Ann Oncol 1994; 5: 609-16.
22. Frobe A, J ones G, J aksic B, B okulic T, B udanec M, I va M, et al. Intraluminal brachytherapy in the management of squamous carcinoma of the esophagus. Dis Esophagus 2009; 22: 513-8.
23. Harbord M, Dawes RFH, B arr H, G iovannini M, V iens P, Eysselein V, et al. Palliation of patients with dysphagia due to advanceDesophageal cancer by endoscopic injection of cisplatin/epinephrine injectable gel. Gastrointest Endosc 2002; 56: 644-51.
24. Hayter CR, H uff-Winters C, Paszat L, Y oussef YM, Shelley WE, Schulze K. A prospective trial of short-course radiotherapy pluSchemotherapy for palliation of dysphagia from advanceDesophageal cancer. Radiother Oncol 2000; 56: 329-33.
25. Homs M Y, Essink-Bot M L, Borsboom G J, Steyerberg EW, Siersema PD, Dutch SIREC Study Group. Quality of life after palliative treatment for oesophageal carcinoma-a prospective comparison between stent placement and single dose brachytherapy. Eur J Cancer 2004; 40: 1862-71.
26. Homs M Y, S teyerberg E W, E ijkenboom W M, T ilanus HW, Stalpers LJ, Bartelsman JF, et al. Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: Multicentre randomised trial. Lancet 2004; 364: 1497-504.
27. Ilson D H, Saltz L, E nzinger P, H uang Y, K ornblith A, Gollub M, et al. Phase II trial of weekly irinotecan plus cisplatin in advanceDesophageal cancer. J Clin Oncol 1999; 17: 3270-5.
28. Jatoi A, T irona M T, C ha SS, A lberts S R, R owland KM, Morton RF, et al. A phase II trial of docetaxeLand CPT-11 in patients with metastatiCadenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia. Int J Gastrointest Cancer 2002; 32: 115-23.
29. Jatoi A, M urphy B R, Foster N R, N ikcevich D A, Alberts S R, Knost JA, et al. Oxaliplatin and capecitabine in patients with metastatiCadenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: A phase II study from the North Central Cancer Treatment Group. Ann Oncol 2006; 17: 29-34.
30. Kassam Z, W ong R K, R ingash J, U ng Y, K amra J, DeBoer G, et al. A phase I/II study to evaluate the toxicity anDefficacy of accelerated fractionation radiotherapy for the palliation of dysphagia from carcinoma of the oesophagus. Clin Oncol (R Coll Radiol) 2008; 20: 53-60.
31. Rao S, Starling N, Cunningham D, Sumpter K, Gilligan D, Ruhstaller T, et al. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as fi rst-line treatment in patients with advanced oesophago-gastric cancer: A randomised, multicentre open-label phase II study. Ann Oncol 2010; 21: 2213-9.
32. Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fl uorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanceDesophagogastric cancer. J Clin Oncol 2002; 20: 1996-2004
33. Rupinski M., Z agorowicz E, Regula J, F ijuth J, K raszewska E, Polkowski M, et al. Randomized comparison of three palliative regimens including brachytherapy, photodynamic therapy, and APC in patients with malignant dysphagia (CONSORT 1a) (Revised II). Am J Gastroenterol 2011; 106: 1612-20.
34. Shenfi ne J, M cNamee P, S teen N, B ond J, G riffi n S M. A randomized controlled clinical trial of palliative therapies for patients with inoperable esophageal cancer. Am J Gastroenterol 2009; 104: 1674-85.
35. Spencer GM, T horpe SM, B lackman GM, S olano J, T obias JS, Lovat LB, et al. Laser augmented by brachytherapy versus laser alone in the palliation of adenocarcinoma of the oesophaguSand cardia: A randomised study. Gut 2002; 50: 224-7.
36. Sumpter K, H arper-Wynne C, C unningham D, R ao S, Tebbutt N, Norman AR, et al. Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fl uorouraciLand oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer 2005; 92: 1976-83.
37. Taeb J, Artru P, B aujat B, M abro M, Carola E, M aindrault F, et al. Optimisation of 5-fl uorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of hydroxyurea, leucovorin, 5-FU and cisplatin (HLFP regimen) for metastatic oesophageal cancer. Eur J Cancer 2002; 38: 661-6.
38. Tebbutt N C, N orman A, C unningham D, I veson T, Seymour M, Hickish T, et al. A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fl uorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer. Ann Oncol 2002; 13: 1568-75.
39. Van Cutsem E, M oiseyenko V M, T julandin S, M ajlis A, Constenla M, Boni C, et al. Phase III study of docetaxeLand cisplatin plus fl uorouracil compared with cisplatin and fl uorouraciLas fi rst-line therapy for advanced gastric cancer: A report of the V325 Study Group. J Clin Oncol 2006; 24: 4991-7.
40. van Meerten E, E skens F A, van Gameren E C, D oorn L, van der GA. First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: A phase II study. Br J Cancer 2007; 96: 1348-52.
41. Webb A, C unningham D, S carffe J H, H arper P, N orman A, Joffe JK, et al. Randomized trial comparing epirubicin, cisplatin, and fl uorouracil versus fl uorouracil, doxorubicin, and methotrexate in advanceDesophagogastric cancer. J Clin Oncol 1997; 15: 261-7
42. O'Hanlon D M, H arkin M, K arat D, S ergeant T, H ayes N, Griffi n SM. Quality-of-life assessment in patients undergoing treatment for oesophageal carcinoma. Br J Surg 1995; 82: 1682-5.
43. Aaronson NK, A hmedzai S, B ergman B, B ullinger M, CulLa, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A qualityof-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-76.
44. de Haes JC, van Knippenberg FC, N eijt JP. M easuring psychologicaLand physical distress in cancer patients: Structure and application of the Rotterdam Symptom Checklist. Br J Cancer 1990; 62: 1034-8.
45. Gaspar LE, Nag S, HerskoviCa, Mantravadi R, Speiser B. American Brachytherapy Society (ABS) consensus guidelines for brachytherapy of esophageal cancer. Clinical Research Committee, American Brachytherapy Society, Philadelphia, PA. Int J Radiat Oncol Biol Phys 1997; 38: 127-32.
46. Young T, De Haes H, C urran D, F ayers P, B randberg Y, Vanvoorden V, et al. Guidelines for assessing quality of life in EORTC clinical trials. Available from: http://groups.eortc.be/ qol/manuals [cited 2012 Oct 3].
47. Blazeby JM, K avadas V, V ickery CW, G reenwood R, Berrisford RG, Alderson D. A prospective comparison of quality of life measures for patients with esophageal cancer. Qual Life Res 2005; 14: 387-93.
48. Fayers PM, A aronson NK, B jordal K, G roenvold M, C urran D, Bottomley A, et al. The EORTC QLQ-C30 Scoring Manual, 3rDed. Available from: http://groups.eortc.be/qol/manuals [cited 2012 Oct 3].
49. Blazeby JM, N icklin J, B rookes ST, W instone K, Alderson D. Feasibility of quality of life assessment in patients with upper gastrointestinal tract cancer. Br J Cancer 2003; 89: 497-501.
50. Ahlner-Elmqvist M, B jordal K, J ordhoy MS, K aasa S, Jannert M. CharacteristicSand implications of attrition in health-related quality of life studies in palliative care. Palliat Med 2009; 23: 432-40.
51. Cocks K, K ing M T, V elikova G, F ayers P M, B rown JM. Quality, interpretation and presentation of European Organisation for Research and Treatment of Cancer quality of life questionnaire core 30 data in randomised controlled trials. Eur J Cancer 2008; 44: 1793-8.
52. Osoba D, R odrigues G, M yles J, Z ee B, Pater J. I nterpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998; 16: 139-44.